XTX Topco Ltd Makes New Investment in CureVac (NASDAQ:CVAC)

XTX Topco Ltd acquired a new stake in CureVac (NASDAQ:CVAC) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 31,646 shares of the company’s stock, valued at approximately $108,000.

Several other institutional investors also recently modified their holdings of CVAC. Platinum Investment Management Ltd. grew its holdings in CureVac by 37.1% during the fourth quarter. Platinum Investment Management Ltd. now owns 497,906 shares of the company’s stock worth $2,096,000 after purchasing an additional 134,626 shares during the period. Tidal Investments LLC bought a new position in shares of CureVac during the 1st quarter worth approximately $175,000. Aristides Capital LLC acquired a new position in shares of CureVac during the 4th quarter worth approximately $100,000. Vanguard Personalized Indexing Management LLC raised its stake in CureVac by 99.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock valued at $147,000 after acquiring an additional 21,999 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in CureVac by 66.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 43,019 shares of the company’s stock valued at $130,000 after purchasing an additional 17,132 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research report on Monday, September 16th.

CureVac Trading Up 1.0 %

Shares of NASDAQ:CVAC opened at $2.97 on Wednesday. CureVac has a 12-month low of $2.21 and a 12-month high of $6.93. The business has a 50 day moving average of $3.25 and a 200-day moving average of $3.26. The company has a quick ratio of 2.28, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a market cap of $664.92 million, a PE ratio of -2.23, a P/E/G ratio of 2.19 and a beta of 2.62.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The firm had revenue of $15.55 million during the quarter, compared to analyst estimates of $10.07 million. CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. As a group, equities research analysts forecast that CureVac will post 0.05 earnings per share for the current year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.